...
首页> 外文期刊>European Journal of Medicinal Chemistry: Chimie Therapeutique >Palladium-mediated synthesis and biological evaluation of C-10b substituted Dihydropyrrolo[1,2-b]isoquinolines as antileishmanial agents
【24h】

Palladium-mediated synthesis and biological evaluation of C-10b substituted Dihydropyrrolo[1,2-b]isoquinolines as antileishmanial agents

机译:钯介导的C-10B取代的二氢吡咯的合成和生物学评价为抗碱基药物

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

The development of new molecules for the treatment of leishmaniasis is, a neglected parasitic disease, is urgent as current anti-leishmanial therapeutics are hampered by drug toxicity and resistance. The pyrrolo[1,2-b]isoquinoline core was selected as starting point, and palladium-catalyzed Heck-initiated cascade reactions were developed for the synthesis of a series of C-10 substituted derivatives. Their in vitro leishmanicidal activity against visceral (L. donovani) and cutaneous (L. amazonensis) leishmaniasis was evaluated. The best activity was found, in general, for the 10-arylmethyl substituted pyrroloisoquinolines. In particular, 2ad (IC50 = 3.30 mu M, SI > 77.01) and 2bb (IC50 = 3.93 mu M, SI > 58.77) were approximately 10-fold more potent and selective than the drug of reference (miltefosine), against L. amazonensis on in vitro promastigote assays, while 2ae was the more active compound in the in vitro amastigote assays (IC50 = 33.59 mu M, SI > 8.93). Notably, almost all compounds showed low cytotoxicity, CC50 > 100 mu g/mL in J774 cells, highest tested dose. In addition, we have developed the first Perturbation Theory Machine Learning (PTML) algorithm able to predict simultaneously multiple biological activity parameters (IC50, K-i, etc.) vs. any Leishmania species and target protein, with high values of specificity (>98%) and sensitivity (>90%) in both training and validation series. Therefore, this model may be useful to reduce time and assay costs (material and human resources) in the drug discovery process. (C) 2021 Elsevier Masson SAS. All rights reserved.
机译:利什曼病是一种被忽视的寄生虫病,由于目前的抗利什曼病治疗方法受到药物毒性和耐药性的阻碍,开发治疗利什曼病的新分子迫在眉睫。以吡咯[1,2-b]异喹啉核为起始点,采用钯催化Heck引发的级联反应合成了一系列C-10取代衍生物。评估了它们对内脏(多诺瓦尼利什曼病)和皮肤(亚马逊利什曼病)利什曼病的体外杀利什曼病活性。总的来说,10-芳基甲基取代的吡咯异喹啉的活性最好。特别是,在体外前鞭毛体试验中,2ad(IC50=3.30μM,SI>77.01)和2bb(IC50=3.93μM,SI>58.77)对亚马逊乳杆菌的有效性和选择性大约是对照药物(米尔曲辛)的10倍,而在体外无鞭毛体试验中,2ae是活性更高的化合物(IC50=33.59μM,SI>8.93)。值得注意的是,几乎所有化合物都显示出低细胞毒性,在J774细胞中CC50>100μg/mL,为最高测试剂量。此外,我们开发了第一个微扰理论机器学习(PTML)算法,能够同时预测多种生物活性参数(IC50、K-i等)与任何利什曼原虫物种和目标蛋白,在训练和验证系列中具有较高的特异性(>98%)和敏感性(>90%)。因此,该模型可能有助于减少药物发现过程中的时间和分析成本(材料和人力资源)。(c)2021爱思唯尔马松SAS。版权所有。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号